Volume 88 Issue 14 | p. 19 | Concentrates
Issue Date: April 5, 2010

Companies Ink siRNA Deals

Department: Business
Keywords: Dicerna, Ipsen, Silence Therapeutics, Dainippon, siRNA

More companies have plans to develop small-interfering-RNA-based drugs. Dicerna Pharmaceuticals and Ipsen will work together to improve the delivery of siRNA. The goal is to make novel conjugates of Dicerna's dicer-substrate siRNA molecules and Ipsen's peptide-targeting vectors to develop therapeutics for oncology and endocrinology. In a separate deal, Silence Therapeutics and Dainippon Sumitomo Pharma have expanded an siRNA delivery pact they initiated in August. The new deal adds . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society